Overview

Update
IPO / Stock
Went Public on Oct 3, 2014 / NASDAQ:DERM
Total Equity Funding
$128M in 3 Rounds from 9 Investors
Headquarters:
Menlo Park, California
Description:
Dermira is a development-stage biotech company focused on developing and commercializing innovative new therapies in dermatology.
Founders:
, , ,
Categories:
Pharmaceutical, Biopharma, Biotechnology
Website:
http://www.dermira.com
Social:

Company Details

Update

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities and includes three late‐stage product candidates, CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis; DRM04, a topical treatment for hyperhidrosis; and, DRM01, a topical sebum inhibitor for the treatment of acne. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.

Funding Rounds (4) - $129.5M

Update
DateAmount / RoundValuationLead InvestorInvestors
Sep, 2016$1.5M / Post Ipo Equity0
Aug, 2014$51M / Series C8
Jun, 2013$35M / Series B4
Oct, 2011$42M / Series A3

Current Team (8)

Update

Offices/Locations (1)

Update
  • Headquarters

    275 Middlefield Road

    Suite #150

    Menlo Park, California 94025

    United States

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos